Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a weekly shot help chinese adults shed significant weight?

NCT ID NCT07792954

Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 28, 2026 · Last updated Sep 04, 2026 · Updated 1 time

Summary

This Phase 3 trial tests whether berobenatide, a once-weekly injection, helps Chinese adults with overweight or obesity lose weight. About 300 participants will receive either berobenatide or a placebo for 48 weeks, with researchers tracking changes in body weight and safety. The study aims to see if the drug can produce meaningful weight loss and potentially reduce the risk of related health problems like heart disease and type 2 diabetes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
berobenatide (PF-08653944), an investigational once-weekly injection
What this could lead to
If it works, berobenatide could offer a new once-weekly treatment option to help people with overweight or obesity achieve meaningful weight loss and reduce related health risks.
What could go wrong
This is an early-stage test in a specific population, and the drug may not prove more effective than placebo or may cause side effects. Results will take time and need confirmation in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults ≥18 years of age. * BMI ≥28 kg/m²; or BMI ≥24 kg/m² and \<28 kg/m² with at least one weight-related comorbidity. * Participants with T2D must have HbA1c 6.5% to 10.0%. * At least one prior unsuccessful dietary weight-loss attempt. Exclusion Criteria: * Significant recent weight change (\>5% within 3 months). * Type 1 diabetes mellitus. * History of pancreatitis. * Personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple endocrine neoplasia type 2 (MEN2). * Recent bariatric surgery or obesity procedures. * Pregnancy or breastfeeding.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Body Weight Obesity obesity disorder Overweight Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity Overweight

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    33 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Affiliated Hospital of Jiangsu University

    Zhenjiang, Jiangsu, 212001, China

  • Affiliated Hospital of Nantong University

    Nantong, Jiangsu, 226001, China

  • Beijing Friendship Hospital

    Beijing, Beijing Municipality, 100050, China

  • Beijing Pinggu Hospital

    Beijing, Beijing Municipality, 101200, China

  • Beijing Tsinghua Changgung Hospital

    Beijing, Beijing Municipality, 102218, China

  • Changzhou Second People's Hospital

    Changzhou, Jiangsu, 213164, China

  • Chongqing People's Hospital

    Chongqing, Chongqing Municipality, 400013, China

  • Chongqing University Three Gorges Hospital

    Chongqing, Chongqing Municipality, 404000, China

  • Hangzhou First People's Hospital

    Hangzhou, Zhejiang, 310006, China

  • Harrison International Peace Hospital

    Hengshui, Hebei, 053000, China

  • Huizhou Central People's Hospital

    Huizhou, Guangdong, 516001, China

  • Jiangxi Provincial People's Hospital

    Nanchang, Jiangxi, 330038, China

  • Jinan Central Hospital

    Jinan, Shandong, 250013, China

  • Luoyang First People's Hospital

    Luoyang, Henan, 471000, China

  • Nanjing First Hospital

    Nanjing, Jiangsu, 210012, China

  • Peking University People's Hospital

    Beijing, Beijing Municipality, 100044, China

  • Pingxiang People's Hospital

    Pingxiang, Jiangxi, 337000, China

  • Pudong New Area People's Hospital Shanghai

    Shanghai, Shanghai Municipality, 201299, China

  • Shanghai Tenth People's Hospital

    Shanghai, Shanghai Municipality, 200072, China

  • Shiyan Taihe Hospital

    Shiyan, Hubei, 442000, China

  • The Fifth People's Hospital of Shanghai

    Shanghai, Shanghai Municipality, 200240, China

  • The First Affiliated Hospital of Henan University of Science &Technology

    Luoyang, Henan, 471023, China

  • The First Affiliated Hospital of Xi'an Medical University

    Xi'an, Shaanxi, 400016, China

  • The Fourth Hospital of Harbin Medical University

    Harbin, Heilongjiang, 150001, China

  • The Second Affiliated Hospital of Nanjing Medical University

    Nanjing, Jiangsu, 210011, China

  • The Second Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, 450014, China

  • The Second Hospital of Hebei Medical University

    Shijiazhuang, Hebei, 050000, China

  • The Second Hospital of Jilin University

    Changchun, Jilin, 130022, China

  • The Second People's Hospital of Hefei

    Hefei, Anhui, 230011, China

  • The first affiliated hospital of Ningbo university

    Ningbo, Zhejiang, 315010, China

  • Tianjin Medical University General Hospital

    Tianjin, 300052, China

  • Wuhan Third Hospital

    Wuhan, Hubei, 430060, China

  • Zhongshan Hospital,Fudan University

    Shanghai, Shanghai Municipality, 200031, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.